Photodynamic therapy for the treatment of port‐wine stains in phakomatosis pigmentovascularis
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Yuanbo Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China. Hauptthemen laut MEDLINE: Port-Wine Stain, Photochemotherapy, Neurocutaneous Syndromes, Hematoporphyrins. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Competency Enhancement Project in the People's Hospital of Jiangsu Province, Scientific Research Project of Wuxi Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Phakomatosis pigmentovascularis (PPV) is a rare congenital syndrome. Only a few studies have reported the treatment of PPV, including a case using photodynamic therapy (PDT) to treat PPV‐associated port‐wine stains (PWS).
Objective
To investigating the efficacy and adverse effects of hemoporfin‐PDT in PPV‐associated PWS.
Methods
The efficacy and adverse effects in patients with PPV who underwent two sessions of hemoporfin‐PDT from January 2019 to December 2022 were retrospectively analyzed.
Results
Twenty patients were included (13 females, 7 males, age range: 2–31 years; mean: 8.20 ± 8.92 years). Two, nine, seven, and two patients had PPV types Ia, IIa, IIb, and IIIa, respectively. After two treatments, the visual evaluation indicated the color of the PWS in 4, 5, 6, and 5 patients showed poor, fair, good, and excellent improvements, respectively. The combined good and excellent improvement rates in patients with PWS and pigmentary nevus overlapping in the same treatment area and in patients with PWS in the treatment areas only were 33.3% versus 87.5%, respectively, and were significantly different ( p = 0.02). Minor side effects, such as edema, scabbing, hyperpigmentation, and blistering, were observed in some patients after PDT.
Conclusion
Hemoporfin‐PDT is an effective treatment for PPV‐associated PWS. Patients with PWS and pigmentary nevus overlapping in the same treatment area showed poorer efficacy than patients with PWS in the treatment areas only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China.
- Department of Dermatology and Venereology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
- Department of General Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
ORCID-Profile: Yuanbo Huang
Förderung
- Clinical Competency Enhancement Project in the People's Hospital of Jiangsu Province
- Scientific Research Project of Wuxi Municipal Health Commission
- National Natural Science Foundation of China
- Top Talent Support Program for young and middle-aged people of Wuxi Health Committee
Zitieren
APA
Huang, Y., Yang, J., Bi, M., Wang, L., Ju, W., Liu, X., Bi, L., Du, Y., Chen, B., & Fan, W. (2024). Photodynamic therapy for the treatment of port‐wine stains in phakomatosis pigmentovascularis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16351
Vancouver
Huang Y, Yang J, Bi M, Wang L, Ju W, Liu X, et al. Photodynamic therapy for the treatment of port‐wine stains in phakomatosis pigmentovascularis. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16351
BibTeX
@article{Huang2024,
author = {Huang, Yuanbo and Yang, Jun and Bi, Mingye and Wang, Lei and Ju, Wen and Liu, Xuan and Bi, Lingbo and Du, Yimei and Chen, Bin and Fan, Weixin},
title = {Photodynamic therapy for the treatment of port‐wine stains in phakomatosis pigmentovascularis},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16351}
}
EUVIMED